CRISPR Archives

crispr therapeutics vertex beta thalassemia

News and Trends 19 Nov 2019

CRISPR Cell Therapy Shows Early Promise for Treating Blood Disorders

CRISPR Therapeutics and its US partner Vertex Pharmaceuticals have released the first clinical results for a cell therapy made using the gene editing tool CRISPR/Cas9 in patients with genetic blood disorders. The interim results concern two patients enrolled in different phase I/II clinical trials testing the same therapy in two blood disorders: transfusion-dependent beta-thalassemia and […]

November 19, 2019 - 3 minutesmins - By Jonathan Smith

More News! 9 Oct 2019

Novo Nordisk and Bluebird Bio to Treat Hemophilia with Gene Editing

The Danish big pharma Novo Nordisk has joined forces with the US gene therapy company bluebird bio to develop next-generation gene editing treatments for hemophilia. The collaboration will last for three years and has the goal of developing a gene therapy that can permanently treat hemophilia A, a genetic disease causing uncontrolled bleeding. Novo Nordisk […]

October 9, 2019 - 1 minutemin - By Jonathan Smith

lightcast discovery cell therapy cambridge uk

Startup Scout 27 Sep 2019

This Biotech Can Screen CAR T-Cells Using Only Light and Microfluidics

Based in Cambridge, UK, Lightcast Discovery is developing microfluidics technology that automates cell screening experiments by using lasers. Mission: To automate cell screening experiments, such as those used when screening CAR T-cell immunotherapies. This would let companies test therapies in complex cell experiments, such as cell-to-cell interactions, which are difficult with traditional drug-screening tools. Cell […]

September 27, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 15 Aug 2019

Swiss Scientists Upgrade CRISPR to Edit Many Genes at Once

A research group at ETH Zurich, Switzerland, has made it possible to edit hundreds of genes at once with CRISPR gene editing. CRISPR gene editing has revolutionized the biotech industry by providing an easy and quick way to genetically modify organisms. So far, however, CRISPR techniques have only managed to edit a maximum of seven […]

August 15, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Jun 2019

CRISPR Therapeutics and Vertex Seal Deal Worth up to €890M

The US giant Vertex Pharmaceuticals is expanding an existing collaboration with the Swiss company CRISPR Therapeutics, paying up to €890M ($1B) to develop treatments for genetic diseases causing muscle weakness using the gene editing tool CRISPR/Cas9. The deal includes €155M ($175M) paid upfront, and potential future payments based on achieving developmental milestones. In exchange, Vertex […]

June 7, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 3 Jun 2019

‘CRISPR Babies’ Might Be at Risk of Dying Younger

Update (01/10/2019): The scientists behind the study have declared that the results were based on erroneous data, meaning the mutation they studied has a weaker effect on mortality than initially reported. A new study highlights the issues that can result from modifying human DNA without sufficient understanding of how it can impact our health. Last […]

June 3, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Startup Scout 24 May 2019

This Biotech Uses Gene Editing to Count Chickens Before They Hatch

In the city of Jerusalem, eggXYt is developing gene edited chickens whose male chicks fluoresce inside the egg. This could prevent the suffering of billions of male chicks in the egg-production industry, which are currently culled after hatching. Mission: To develop a gene edited breed of chickens whose sex can be determined before hatching using […]

May 24, 2019 - 3 minutesmins - By Jonathan Smith

Interview 6 May 2019

2019 Will Be a “Year of Realism” for Biotech Investments

Biotech investors regularly jump on new crazes, including the microbiome and CRISPR-Cas9 gene editing. At BIO-Europe Spring 2019, Regina Hodits, Managing Partner at German VC firm Wellington Partners Life Sciences, spoke to us about the firm’s realistic approach to biotech investment. Biotechnology is an industry with high risks and high rewards. Before a medical biotech […]

May 6, 2019 - 6 minutesmins - By Jonathan Smith

crispr cas9 cassava crop virus resistance

News and Trends 29 Apr 2019

Viruses Evolve to Defeat CRISPR-Cas9 in Genetically-Modified Plants

Researchers found that viral pathogens can quickly evolve to overcome transgenic cassava plants expressing the bacterial weapon CRISPR-Cas9, which could have major regulatory implications. Geminiviruses are pathogens that kill off crops such as beans, cotton and cassava plants. Past efforts to breed plants that are resistant to infection have not been successful. One potential method […]

April 29, 2019 - 2 minutesmins - By Jonathan Smith

Interview 8 Apr 2019

Francis Mojica, the Spanish Scientist Who Discovered CRISPR

Contrary to popular belief, Francis Mojica was the first person to discover the CRISPR mechanism and give it its name. He told me how the discovery came about, discussed the wide potential of the gene editing tool and shared his favorite CRISPR application. You’ve likely heard of CRISPR/Cas9, a gene editing tool that has taken […]

April 8, 2019 - 11 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Mar 2019

Danish Biotech to Develop CRISPR-Based Microbiome Treatments

SNIPR Biome has raised €43M in Series A funds to develop treatments that precisely target ‘bad’ bacteria using CRISPR gene editing, while keeping the rest of the patient’s microbiome intact. Founded with €2.6M seed investment from the Lundbeck Foundation in 2017, SNIPR Biome was the first exploratory investment for the Danish organisation’s Emerge fund, which […]

March 11, 2019 - 2 minutesmins - By Helen Albert

CRISPR Cas9 antimicrobial peptide antibiotic resistance

News and Trends 26 Feb 2019

Swiss Scientists Find ‘Silver Bullet’ Against Bacterial Infections

Using the gene editing tool CRISPR-Cas9, researchers in Lausanne have uncovered antimicrobial molecules in the fruit fly that can selectively kill certain bacteria. This could lead to new therapeutics combatting antimicrobial resistance, and even preventing infections before they start. The research shows the antimicrobial molecules, or peptides, have the potential to treat infections of pathogens […]

February 26, 2019 - 3 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us